{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T01:52:56Z","timestamp":1790992376758,"version":"4.1.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologie"],"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>In dieser Fallserie berichten wir \u00fcber 3\u00a0Patientinnen, die im zeitlichen Zusammenhang mit einer postpartalen Blutung und in diesem Rahmen erfolgter Blutstillung mittels einer Chitosan-Tamponade das klinische Bild eines Cogan-I-Syndroms (\u201eokulovestibuloauditorisches Syndrom\u201c) entwickelten. Alle 3\u00a0Patientinnen zeigten die f\u00fcr das Cogan-I-Syndrom typische Befundkonstellation aus interstitieller Keratitis, (Pan\u2011)Uveitis, Schwindel und H\u00f6rverlust. Zus\u00e4tzlich bestanden Kopfschmerzen. Die Uveitis besserte sich in den berichteten F\u00e4llen rasch unter lokaler und systemischer Steroidtherapie, w\u00e4hrend die vestibuloauditorischen Symptome und Zephalgien ein verz\u00f6gertes Ansprechen zeigten. Der zeitliche Zusammenhang sowie der konsistente Symptomkomplex lassen an eine m\u00f6gliche Assoziation mit dem vorausgegangenen Geburtsereignis und der Chitosan-Tamponade denken. Vor diesem Hintergrund sollte eine Chitosan-Tamponade \u2013\u00a0wenn aus geburtsmedizinischer Sicht m\u00f6glich\u00a0\u2013 vermieden werden und im Falle eines Einsatzes unbedingt an die m\u00f6gliche Assoziation zu dem beschriebenen Krankheitsbild gedacht werden. Die betroffenen Patientinnen sollten fr\u00fchzeitig interdisziplin\u00e4r unter Einbeziehung der Augenheilkunde, Geburtsmedizin, Hals-Nasen-Ohren-Heilkunde und Rheumatologie betreut werden.<\/jats:p>","DOI":"10.1007\/s00347-026-02527-4","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T12:22:08Z","timestamp":1790943728000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Uveitis, H\u00f6rverlust und Schwindel nach Einlage einer Chitosan-Tamponade im Rahmen einer postpartalen H\u00e4morrhagie\u00a0\u2013 \u201ePostpartales Cogan-I-Syndrom\u201c","Uveitis, loss of hearing and vertigo after placement of a chitosan tamponade for postpartum hemorrhage\u2014Postpartum Cogan syndrome"],"prefix":"10.1007","author":[{"given":"K.","family":"L\u00f6w","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Wilmes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Sharaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Altay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Theocharidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Schott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Strunk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Oda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Pleyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Klu\u00dfmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Groten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Cursiefen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6815-0617","authenticated-orcid":false,"given":"A.","family":"Lentzsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,2]]},"reference":[{"key":"2527_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1055\/s-2008-1035341","volume":"207","author":"U Pleyer","year":"1995","unstructured":"Pleyer\u00a0U, Baykal\u00a0HE, Rohrbach\u00a0JM et\u00a0al (1995) Cogan I syndrome: too often detected too late? A contribution to early diagnosis of Cogan I syndrome. Klin Monbl Augenheilkd 207:3\u201310","journal-title":"Klin Monbl Augenheilkd"},{"key":"2527_CR2","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/S0025-6196(12)61951-X","volume":"61","author":"RS Vollertsen","year":"1986","unstructured":"Vollertsen\u00a0RS, Mcdonald\u00a0TJ, Younge\u00a0BR et\u00a0al (1986) Cogan\u2019s syndrome: 18\u00a0cases and a\u00a0review of the literature. Mayo Clin Proc 61:344\u2013361","journal-title":"Mayo Clin Proc"},{"key":"2527_CR3","doi-asserted-by":"crossref","unstructured":"Mala N, Zweigart G, Fiedler LS (2024) Multidisciplinary unravelling Cogan\u2019s syndrome post-C-section: insights into diagnosis, treatment and a\u00a0possible identified new trigger. BMJ Case Rep\u00a017","DOI":"10.1136\/bcr-2024-261520"},{"key":"2527_CR4","unstructured":"Dggg O, Sggg S (2022) Peripartal haemorrhage, diagnosis and therapy. (S2k-Level, AWMF Registry No. 015\/063)"},{"key":"2527_CR5","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1515\/jpm-2021-0533","volume":"50","author":"C Biele","year":"2022","unstructured":"Biele\u00a0C, Radtke\u00a0L, Kaufner\u00a0L et\u00a0al (2022) Does the use of chitosan covered gauze for postpartum hemorrhage reduce the need for surgical therapy including hysterectomy? A\u00a0databased historical cohort study. J\u00a0Perinat Med 50:1078\u20131086","journal-title":"J Perinat Med"},{"key":"2527_CR6","first-page":"113","volume":"61","author":"DG Cogan","year":"1963","unstructured":"Cogan\u00a0DG (1963) Non-Syphilitic Interstitial Keratitis with Vestibulo-Auditory Symptoms\u2011A Case with Fatal Aortitis. Trans Am Ophthalmol Soc 61:113\u2013121","journal-title":"Trans Am Ophthalmol Soc"},{"key":"2527_CR7","doi-asserted-by":"crossref","unstructured":"Beckers D, Pleyer U, Beckers L et\u00a0al. (2025) Bilateral acute intermediate uveitis following intrauterine Chitosan tamponade: a\u00a0case series. J\u00a0Ophthalmic Inflamm Infect","DOI":"10.1186\/s12348-025-00548-9"},{"key":"2527_CR8","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.jogoh.2017.08.003","volume":"46","author":"G Carles","year":"2017","unstructured":"Carles\u00a0G, Dabiri\u00a0C, Mchirgui\u00a0A et\u00a0al (2017) Uses of chitosan for treating different forms of serious obstetrics hemorrhages. J\u00a0Gynecol Obstet Hum Reprod 46:693\u2013695","journal-title":"J Gynecol Obstet Hum Reprod"},{"key":"2527_CR9","unstructured":"Ltd. MP (2025) Dringende Sicherheitswarnung im Feld CELOX PPH Geb\u00e4rmuttertamponade zur Blutstillung. (Ref.-Nr. FSN 2025:001)"},{"key":"2527_CR10","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1080\/14712598.2019.1611779","volume":"19","author":"R Padoan","year":"2019","unstructured":"Padoan\u00a0R, Cazzador\u00a0D, Pendolino\u00a0AL et\u00a0al (2019) Cogan\u2019s syndrome: new therapeutic approaches in the biological era. Expert Opin Biol Ther 19:781\u2013788","journal-title":"Expert Opin Biol Ther"}],"container-title":["Die Ophthalmologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-026-02527-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00347-026-02527-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-026-02527-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T01:04:12Z","timestamp":1790989452000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00347-026-02527-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,2]]},"references-count":10,"alternative-id":["2527"],"URL":"https:\/\/doi.org\/10.1007\/s00347-026-02527-4","relation":{},"ISSN":["2731-720X","2731-7218"],"issn-type":[{"value":"2731-720X","type":"print"},{"value":"2731-7218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,2]]},"assertion":[{"value":"22 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.\u00a0Strunk erhielt Beratungshonorare von Novartis, BMS, Boehringer, Reisekosten von AbbVie, Johnson & Johnson und ist Referent f\u00fcr AbbVie, Johnson & Johnson, Pfizer, Sanofi, UCB. U.\u00a0Pleyer erhielt Research grant\u00a0\u2013 Immune modulation in ophthalmology, Beratungshonorare von AbbVie, Santen, Th\u00e9a, ist Referent f\u00fcr AbbVie, Allergan, Alimera, Bayer, Novartis, Pfizer, Roche, Santen, Th\u00e9a und Patente EP\u00a019732357.9, PCT\/EP2019\/066419. K.\u00a0L\u00f6w, M.\u00a0Wilmes, K.\u00a0Sharaf, F.\u00a0Steinberg, L.\u00a0Altay, C.\u00a0Theocharidou, S.\u00a0Schott, H.\u00a0Oda, J.\u00a0Klu\u00dfmann, T.\u00a0Groten, C.\u00a0Cursiefen und A.\u00a0Lentzsch geben an, dass kein Interessenkonflikt besteht.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patient\/-innen zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern\/Vertreterinnen eine schriftliche Einwilligung vor.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}